A Phase 1b/2a Two-Part Open-Label Multicenter Study to Evaluate the Safety and Efficacy of LY2880070 as Monotherapy and in Combination With Gemcitabine in Patients With Advanced or Metastatic Cancer

Trial Profile

A Phase 1b/2a Two-Part Open-Label Multicenter Study to Evaluate the Safety and Efficacy of LY2880070 as Monotherapy and in Combination With Gemcitabine in Patients With Advanced or Metastatic Cancer

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 21 Jun 2017

At a glance

  • Drugs LY 2880070 (Primary) ; Gemcitabine
  • Indications Breast cancer; Colon cancer; Colorectal cancer; Ovarian cancer; Rectal cancer; Solid tumours
  • Focus Adverse reactions
  • Sponsors Esperas Pharma
  • Most Recent Events

    • 13 Jun 2017 Planned primary completion date changed from 1 Sep 2017 to 1 Nov 2017.
    • 13 Jan 2017 Planned primary completion date changed from 1 Apr 2020 to 1 Sep 2017.
    • 27 May 2016 Status changed from not yet recruiting to recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top